Semaglutide Orsema 0,5 mg

Buy Orsema Online In Australia, CA, UK and USA

Semaglutide is a GLP-1 receptor analogue which is 94% identical with human GLP-1. Semaglutide is a GLP-1 receptor agonist that binds to the specific GLP-1 receptors and activates them. Semaglutide has glucose-lowering action through insulin secretion stimulation and suppression of glucagon secretion when the glucose level is high.

The effect of blood glucose reduction also includes a slight impairment in gastric emptying time. In hypoglycemic state, Semaglutide decreases insulin release and has no effect on glucagon release. Semaglutide has been further observed to cause overall weight and fat loss through a decrease in appetite.

Semaglutide Orsema for sale - Indications

• A supplement to diet and exercise for the management of glycemia in adults with type 2 diabetes mellitus

• To mitigate the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease

Dosage & Administration

The initial dose of the drug is 0.25 per week. After 4 weeks, the dose should be increased to 0. 5 mg once weekly. At least 4 weeks of treatment with the dose of 0. If 5 mg once weekly is not sufficient to control glucose levels, 1 mg once weekly should be given to further manage the condition. Doses above 1 mg per week should not be taken.  Semaglutide should be given once weekly with no regard to time of day or meals.

Semaglutide is to be injected subcutaneously in the abdominal area, thigh or in the upper arm. The injection site can be altered without a change in the dose given. It must not be given intravenously or intramuscularly. The day of weekly administration can be changed if necessary as long as the time between two doses is at least 3 days with more than 72 hours. When a new dosing day has been chosen, the patient should continue to take the medication once a week.

Precautions

Diabetic Ketoacidosis: Semaglutide should not be used in individuals with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.

Pancreatitis: Discontinue Semaglutide immediately if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.

Diabetic Retinopathy: Patients with diabetic retinopathy should be carefully monitored.

Use in Pregnancy & Lactation

Semaglutide is contraindicated in pregnancy. It is recommended that Semaglutide be stopped at least 2 months before a patient desires to become pregnant. Since the risk to a breastfed child cannot be ruled out, semaglutide should not be used in breast-feeding women.

Drug Interaction

Semaglutide slows down the emptying of the stomach and may affect the rate of absorption of orally administered drug products co-administered with semaglutide. Semaglutide should be used with caution in patients who are on oral medications that are dependent on the rapid absorption through the gastrointestinal tract.

OverDose

Overdoses of up to 4 mg in a single dose and up to 4 mg in a week have been reported in clinical trials, with nausea being the most common adverse reaction. There is no specific antidote for a Semaglutide overdose. Supportive treatment should be provided based on the patient's clinical symptoms.

Storage

Refrigerate at 2 C to 8 C. Do not freeze. Do not use it within the reach of children.

Commercial Pack

OrsemaTM 0. 25 mg Injection: Each box includes one pre-filled syringe of Semaglutide 0. 25 mg Injection.

OrsemaTM 0. 50 mg Injection: Each box contains 1 pre-filled syringe of Semaglutide 0. 50 mg Injection.

Buy Orsema in Australia, UK, CA and USA using a Credit Card and Paypal